TY - JOUR
T1 - Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
N1 - Funding Information:
Supported in part by grants CA62242 and CA107476 from the National Cancer Institute.
PY - 2007/12
Y1 - 2007/12
N2 - In 1978, the term "monoclonal gammopathy of undetermined significance" (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10% plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.
AB - In 1978, the term "monoclonal gammopathy of undetermined significance" (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10% plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.
UR - http://www.scopus.com/inward/record.url?scp=35748932962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35748932962&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2007.08.005
DO - 10.1016/j.hoc.2007.08.005
M3 - Review article
C2 - 17996590
AN - SCOPUS:35748932962
SN - 0889-8588
VL - 21
SP - 1093
EP - 1113
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 6
ER -